0.000
Close （ET）Quotes delayed by 15 min
--Market Cap
--P/E TTM
More Details of Intra-Cellular Therapies Inc Company
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Company Info
Ticker SymbolITCI
Company nameIntra-Cellular Therapies Inc
IPO dateJan 31, 2014
CEODr. Sharon Mates, Ph.D.
Number of employees860
Security typeOrdinary Share
Fiscal year-endJan 31
Address135 Route 202/206
CityBEDMINSTER
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code07921
Phone16464409333
Websitehttps://www.intracellulartherapies.com/
Ticker SymbolITCI
IPO dateJan 31, 2014
CEODr. Sharon Mates, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Sanjeev Narula
Mr. Sanjeev Narula
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
--
--
Dr. Suresh K. Durgam, M.D.
Dr. Suresh K. Durgam, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. Mark Neumann
Mr. Mark Neumann
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Michael I. Halstead, J.D.
Mr. Michael I. Halstead, J.D.
President
President
--
--
Dr. Sharon Mates, Ph.D.
Dr. Sharon Mates, Ph.D.
Chief Executive Officer
Chief Executive Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sanjeev Narula
Mr. Sanjeev Narula
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
--
--
Dr. Suresh K. Durgam, M.D.
Dr. Suresh K. Durgam, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. Mark Neumann
Mr. Mark Neumann
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Michael I. Halstead, J.D.
Mr. Michael I. Halstead, J.D.
President
President
--
--
Dr. Sharon Mates, Ph.D.
Dr. Sharon Mates, Ph.D.
Chief Executive Officer
Chief Executive Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Feb 21
Updated: Fri, Feb 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
10.38%
The Vanguard Group, Inc.
9.11%
BlackRock Institutional Trust Company, N.A.
5.00%
Alafi Capital Company, LLC
4.45%
JP Morgan Asset Management
4.14%
Other
66.92%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
10.38%
The Vanguard Group, Inc.
9.11%
BlackRock Institutional Trust Company, N.A.
5.00%
Alafi Capital Company, LLC
4.45%
JP Morgan Asset Management
4.14%
Other
66.92%
Shareholder Types
Shareholders
Proportion
Venture Capital
4.46%
Individual Investor
0.82%
Investment Advisor
0.44%
Hedge Fund
0.41%
Pension Fund
0.14%
Investment Advisor/Hedge Fund
0.09%
Sovereign Wealth Fund
0.07%
Family Office
0.01%
Family Office
0.01%
Other
93.55%
Institutional Shareholding
Updated: Mon, Jan 20
Updated: Mon, Jan 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
3
971.78K
0.92%
+971.78K
2024Q4
766
106.57M
100.29%
-3.63M
2024Q3
729
104.78M
99.19%
-5.56M
2024Q2
708
104.89M
99.37%
+2.02M
2024Q1
666
96.98M
100.19%
-6.24M
2023Q4
642
98.04M
101.70%
-2.07M
2023Q3
619
95.67M
99.43%
-2.42M
2023Q2
605
92.90M
96.72%
-4.13M
2023Q1
591
92.61M
96.92%
-6.74M
2022Q4
583
91.86M
96.95%
-7.98M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
--
0%
-8.41M
-100.00%
The Vanguard Group, Inc.
--
0%
-201.85K
-100.00%
BlackRock Institutional Trust Company, N.A.
--
0%
-102.31K
-100.00%
Alafi Capital Company, LLC
--
0%
--
--
Norges Bank Investment Management (NBIM)
--
0%
+1.27M
-100.00%
View more
Related ETFs
Updated: Sun, Apr 6
Updated: Sun, Apr 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
6.51%
AdvisorShares Psychedelics ETF
5.54%
AltShares Merger Arbitrage ETF
4.68%
iShares U.S. Pharmaceuticals ETF
4.32%
First Trust NYSE Arca Biotechnology Index Fund
4.21%
ProShares Merger ETF
3.64%
SPDR S&P Pharmaceuticals ETF
3.6%
First Trust Merger Arbitrage ETF
3.44%
First Trust Health Care Alphadex Fund
2.66%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.51%
View more
iShares Neuroscience and Healthcare ETF
Proportion6.51%
AdvisorShares Psychedelics ETF
Proportion5.54%
AltShares Merger Arbitrage ETF
Proportion4.68%
iShares U.S. Pharmaceuticals ETF
Proportion4.32%
First Trust NYSE Arca Biotechnology Index Fund
Proportion4.21%
ProShares Merger ETF
Proportion3.64%
SPDR S&P Pharmaceuticals ETF
Proportion3.6%
First Trust Merger Arbitrage ETF
Proportion3.44%
First Trust Health Care Alphadex Fund
Proportion2.66%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.51%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
